Literature DB >> 7961869

The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.

Y Singh1, K R Klimpel, N Arora, M Sharma, S H Leppla.   

Abstract

The protective antigen (PA) component of anthrax toxin contains two sites that are uniquely sensitive to proteolytic cleavage. Cleavage at the sequence RKKR167 by the cellular protease furin is absolutely required for toxicity, whereas cleavage by chymotrypsin or thermolysin at the sequence FFD315 inactivates the protein, apparently by blocking the ability of PA to translocate the catalytic moieties of the toxins, lethal factor (LF) and edema factor (EF), to the cytosol of eukaryotic cells. To specify the role of the chymotrypsin-sensitive site of PA in the translocation of LF, we altered residues 313-315. None of the mutations in this region interfered with the ability of PA to bind to its cellular receptor, be cleaved by cell surface furin, and bind LF. Substitution of Ala for Asp315 or for both Phe313 and Phe314 reduced the ability of PA to intoxicate cells in the presence of LF by 3- and 7-fold, respectively. Substitution of Phe313 by Cys greatly reduced the rate of LF translocation and delayed toxicity. The rate at which the Cys-substituted PA killed cells was increased significantly by blocking the sulfhydryl group with iodoacetamide, suggesting that this added Cys interacts with cellular proteins and slows translocation of LF. Deletion of the 2 Phe rendered PA completely non-toxic. This deleted PA protein lacked the ability shown by native PA to form oligomers on cells and in solution and to induce release of 86Rb from Chinese hamster ovary cells. These results suggest that the chymotrypsin-sensitive site in PA is required for membrane channel formation and translocation of LF into the cytosol. PA double mutants were constructed that cannot be cleaved at either the furin or chymotrypsin sites. These PA proteins were more stable in Bacillus anthracis culture supernatants and may therefore be useful as a replacement for PA in anthrax vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961869

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells.

Authors:  Masahiro Nagahama; Koichi Nagayasu; Keiko Kobayashi; Jun Sakurai
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Authors:  Joseph A Bellanti; Feng-Ying C Lin; Chiayung Chu; Joseph Shiloach; Stephen H Leppla; German A Benavides; Arthur Karpas; Mahtab Moayeri; Chunyan Guo; John B Robbins; Rachel Schneerson
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

3.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Daniel Feldman; Fen Yu; Kemp B Cease
Journal:  Vaccine       Date:  2014-11-30       Impact factor: 3.641

5.  A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

Authors:  Mahtab Moayeri; Clinton E Leysath; Jacqueline M Tremblay; Catherine Vrentas; Devorah Crown; Stephen H Leppla; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

6.  Host cell cytotoxicity and cytoskeleton disruption by CerADPr, an ADP-ribosyltransferase of Bacillus cereus G9241.

Authors:  Nathan C Simon; James M Vergis; Avesta V Ebrahimi; Christy L Ventura; Alison D O'Brien; Joseph T Barbieri
Journal:  Biochemistry       Date:  2013-03-20       Impact factor: 3.162

7.  Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.

Authors:  Jon Oscherwitz; Conrad P Quinn; Kemp B Cease
Journal:  Vaccine       Date:  2015-03-26       Impact factor: 3.641

8.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

9.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

10.  Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Kemp B Cease
Journal:  Clin Vaccine Immunol       Date:  2013-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.